NASDAQ$MREO
Mereo Biopha-Adr · Q1 2025 earnings
Q1 2025 earnings · · After market close · Investor relations
Briefing
Mereo BioPharma reported its financial results for the first quarter ended March 31, 2025, highlighting continued progress in its Phase 3 Orbit study and a strong cash position.
Mereo BioPharma reported a net loss of $12.9 million for the first quarter of 2025, compared to a net loss of $9.0 million in the same period last year. The company's cash and cash equivalents stood at $62.5 million as of March 31, 2025, which is expected to fund operations into 2027. Progress continues in the Phase 3 Orbit study of setrusumab, with a read-out anticipated in mid-2025 or Q4 2025.
- Net loss for Q1 2025 was $12.9 million, an increase from $9.0 million in Q1 2024.
- Cash and cash equivalents were $62.5 million as of March 31, 2025, down from $69.8 million at the end of 2024.
- The Phase 3 Orbit study for setrusumab is on track for a second interim analysis in mid-2025 or final analysis in Q4 2025.
- Alvelestat is now Phase 3 ready, with start-up activities for the pivotal study ongoing and discussions with potential partners underway.
Headline financials
Revenue & EPS history
Mereo Biopha-Adr · Revenue · Quarterly
$0
Forward guidance
Mereo BioPharma anticipates 2025 to be a significant year with key milestones, including the read-out of the Phase 3 Orbit study. The company expects its current cash and cash equivalents to fund operations into 2027, excluding potential upfront payments from new partnerships.
Tailwinds
- Phase 3 Orbit study of setrusumab remains on track for read-out in mid-2025 or Q4 2025.
- Continued investment in pre-commercial activities for setrusumab in Europe to enable a successful launch.
- Alvelestat is now Phase 3 ready, with start-up activities for the pivotal study ongoing.
- Ongoing discussions with multiple potential development and commercialization partners for alvelestat.
- Existing cash and cash equivalents are expected to fund operations into 2027.
Headwinds
- Guidance does not include any potential upfront payments associated with a partnership for alvelestat.
- Guidance does not include any potential upfront payments from business development activity around non-core programs.
- The company's financial performance is subject to the inherent uncertainties of the clinical development process.
- Reliance on third parties for funding and conduct of clinical trials poses a risk.
- Dependence on patient enrollment in clinical trials and key executives could impact future developments.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 12 quarterly earnings reports · overlaid with Q1 2025
+3.4%
Avg return
Earnings day
+0.4%
Avg return
5 days after
+17.3%
Avg return
30 days after
69%
9 / 13 earnings
Positive
+11.9%
Q4 2023
Best reaction
-6.1%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.1% | +0.9% | — | |
| Q4 2025 | +4.6% | -4.5% | -4.3% | |
| Q3 2025 | +6.3% | +0.6% | +27.1% | |
| Q2 2025 | +9.4% | +14.5% | +19.7% | |
| Q1 2025 | +1.3% | -2.2% | +25.3% | |
| Q4 2024 | -3.6% | -11.6% | +15.6% | |
| Q3 2023 | -5.4% | -17.5% | -12.9% | |
| Q3 2024 | -5.4% | -17.5% | -12.9% | |
| Q2 2024 | +6.2% | +16.4% | +18.0% | |
| Q1 2023 | +10.5% | +10.1% | +43.6% | |
| Q1 2024 | +10.5% | +10.1% | +43.6% | |
| Q4 2023 | +11.9% | +15.6% | -7.1% | |
| Q4 2022 | -6.1% | -10.3% | +52.3% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro